- Cornerstone Therapeutics (CRTX +4.2%) moves higher on a solid Q2, reporting earnings of $0.19 per share and beating consensus estimates of $0.12.
- Revenues were $40.4M, up 88% Y/Y and above the analyst estimate of $35.79M. In the same period last year, the company reported $0.17 loss per share on revenues of $21.5M.
- Gross margin of 75%, compared to 59% in Q212, primarily due to the addition of CARDENE I.V., as well as growth in net product sales resulting from price increases and lower estimated rates for certain sales allowances.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs